CRISPR/Cas9‐Multiplexed Editing of Chinese Hamster Ovary B4Gal‐T1, 2, 3, and 4 Tailors N‐Glycan Profiles of Therapeutics and Secreted Host Cell Proteins
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
In production of recombinant proteins for biopharmaceuticals, N‐glycosylation is often important for protein efficacy and patient safety. IgG with agalactosylated (G0)‐N‐glycans can improve the activation of the lectin‐binding complement system and be advantageous in the therapy of lupus and virus diseases. In this study, the authors aimed to engineer CHO‐S cells for the production of proteins with G0‐N‐glycans by targeting B4Gal‐T isoform genes with CRISPR/Cas9. Indel mutations in genes encoding B4Gal‐T1, ‐T2, and ‐T3 with and without a disrupted B4Gal‐T4 sequence resulted in only ≈1% galactosylated N‐glycans on total secreted proteins of 3‐4 clones per genotype. The authors revealed that B4Gal‐T4 is not active in N‐glycan galactosylation in CHO‐S cells. In the triple‐KO clones, transiently expressed erythropoietin (EPO) and rituximab harbored only ≈6% and ≈3% galactosylated N‐glycans, respectively. However, simultaneous disruption of B4Gal‐T1 and ‐T3 may decrease cell growth. Altogether, the authors present the advantage of analyzing total secreted protein N‐glycans after disrupting galactosyltransferases, followed by expressing recombinant proteins in selected clones with desired N‐glycan profiles at a later stage. Furthermore, the authors provide a cell platform that prevalently glycosylates proteins with G0‐N‐glycans to further study the impact of agalactosylation on different in vitro and in vivo functions of recombinant proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biopharmaceutical benchmarks 2014
Walsh, G. (2014) · Nature Biotechnology · doi:10.1038/nbt.3040 · Cited by 1,008
Malhotra, R., Wormald, M. R., Rudd, P. M., Fischer, P. B., Dwek, R. A., & Sim, R. B. (1995) · Nature Medicine · doi:10.1038/nm0395-237 · Cited by 786
The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line
Xu, X., Nagarajan, H., Lewis, N. E., Pan, S., Cai, Z., Liu, X., Chen, W., Xie, M., Wang, W., Hammond, S., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1932 · Cited by 785
Self-citationGoetze, A. M., Liu, Y. D., Zhang, Z., Shah, B., Lee, E., Bondarenko, P. V., & Flynn, G. C. (2011) · Glycobiology · doi:10.1093/glycob/cwr027 · Cited by 467
Kanda, Y., Yamada, T., Mori, K., Okazaki, A., Inoue, M., Kitajima-Miyama, K., Kuni-Kamochi, R., Nakano, R., Yano, K., Kakita, S., et al. (2007) · Glycobiology · doi:10.1093/glycob/cwl057 · Cited by 372
Asano, M., Furukawa, K., Kido, M., Matsumoto, S., Umesaki, Y., Kochibe, N., & Iwakura, Y. (1997) · The EMBO Journal · doi:10.1093/emboj/16.8.1850 · Cited by 270
Engineered CHO cells for production of diverse, homogeneous glycoproteins
Yang, Z., Wang, S., Halim, A., Schulz, M. A., Frodin, M., Rahman, S. H., Vester-Christensen, M. B., Behrens, C., Kristensen, C., Vakhrushev, S. Y., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3280 · Cited by 254 · cited 11×
“In a previous study in CHO-K1 derived cell lines, disruption of B4Gal-T1, -T2 and –T3 resulted in prevalently agalactosylated N-glycans on rituximab and EPO whereas the effects of B4Gal-T disruptions on cell growth and the glycosylation of total secreted proteins were not addressed[34].”
BackgroundMethodResultInfluentialIida, S., Misaka, H., Inoue, M., Shibata, M., Nakano, R., Yamane-Ohnuki, N., Wakitani, M., Yano, K., Shitara, K., & Satoh, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2619 · Cited by 206
Yu, M., Brown, D., Reed, C., Chung, S., Lutman, J., Stefanich, E., Wong, A., Stephan, J.-P., & Bayer, R. (2012) · mAbs · doi:10.4161/mabs.20737 · Cited by 203 · cited 1×
“HM structures are a critical quality attribute within biopharmaceutical protein production[41] and can accumulate during cell culture performance.”
BackgroundRonda, C., Pedersen, L. E., Hansen, H. G., Kallehauge, T. B., Betenbaugh, M. J., Nielsen, A. T., & Kildegaard, H. F. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25233 · Cited by 195 · cited 2×
“[36] Ronda, C., Pedersen, L.E., Hansen, H.G., Kallehauge, T.B., et al., Accelerating genome editing in CHO cells using CRISPR Cas9 and CRISPy, a web-based target finding tool.”
MethodSelf-citation
Cited by
Amann, T., Schmieder, V., Faustrup Kildegaard, H., Borth, N., & Andersen, M. R. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.27101 · Cited by 46
“To establish such homogenous N-glycans, multiple glycosyltransferases were disrupted via CRISPR/Cas9 or ZFN by either introducing InDels or by removing the complete gene sequence (Amann et al., 2018; Amann et al., 2019; Bydlinski et al., 2018; Yang et al., 2015).”
Self-citationGlycoengineering Chinese hamster ovary cells: a short history
Donini, R., Haslam, S. M., & Kontoravdi, C. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200840 · Cited by 37
Transcriptome Analysis of CHO Cell Size Increase During a Fed-Batch Process
Pan, X., Alsayyari, A. A., Dalm, C., Hageman, J. A., Wijffels, R. H., & Martens, D. E. (2019) · Biotechnology Journal · doi:10.1002/biot.201800156 · Cited by 22
Metadata
- Authors
- Amann, T., Hansen, A. H., Kol, S., Lee, G. M., Andersen, M. R., & Kildegaard, H. F.
- Venue
- Biotechnology Journal
- Publisher
- Wiley
- Published
- 2018-07-02
- Volume
- 13
- Issue
- 10
- Pages
- e1800111-e1800111
- ISSN
- 1860-6768 (ISSN-L)
- 1860-7314
- OpenAlex
- W2806198647
- Cited by
- 37
- References
- 12
- FWCI
- 1.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.